Efficacy, Tolerability, and Biomarker Analyses of Once‐Every‐2‐Weeks Cetuximab Plus First‐Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild‐Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Colorectal Cancer"
DOI: 10.1016/j.clcc.2016.08.005
Abstract: Micro‐Abstract The nonrandomized phase 2 APEC trial investigated first‐line once‐every‐2‐weeks cetuximab plus chemotherapy (investigator's choice of FOLFOX or FOLFIRI) studied patients with KRAS/RAS wild‐type metastatic colorectal cancer. We observed an activity and safety profile similar… read more here.
Keywords: folfox folfiri; weeks cetuximab; line; first line ... See more keywords